Posted inPress releases

FDA Accepts Professor Niazi’s Petition to Allow Interchangeable Status to Biosimilars without Additional Clinical Testing–A rational step towards removing misconceptions about biosimilars

CHICAGO, June 24, 2024 /PRNewswire/ — According to Pharmaceutical Scientist, Inc., biosimilars are copies of biological drugs introduced after the expiry of the patents or exclusivity of new biological drugs as a more affordable choice for patients. In the US, the legislation has also created an interchangeable class of biosimilars that requires extensive clinical efficacy […]

Verify your email

We'll send a verification code to .

Gift this article